Skip to main content
An official website of the United States government
Email

Publications from the Nanotechnology Characterization Lab

Recent Publications 

Advancing medical applications of cancer nanotechnology: Highlighting two decades of the NCI'S Nanotechnology Characterization Laboratory service to the research community.
Crist RM, Barenholz Y, Cern A, Clark KN, Cullis PR, Dean C, Desai N, Ferrari M, Germain M, Giacomantonio CA, Grabarnik E, Grodzinski P, Hod A, Kennedy BE, Kularatne RN, Kwon GS, Loeb E, Noftall EB, Pagliaro L, Rasoulianboroujeni M, Roth A, Rowles D, Singh K, Steinmetz NF, Yehtina Z, Zhang Y, Zilbersheid D, Clogston JD, Stern ST, Dobrovolskaia MA.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2025;17(3):e70020. [PubMed Abstract]

Changes in generations of PAMAM dendrimers and compositions of nucleic acid nanoparticles govern delivery and immune recognition.
Avila YI, Rebolledo LP, Leal Santos N, Rawlins B, Radwan Y, Andrade-Munoz M, Skelly E, Chandler MR, Andrade LNS, Kim TJ, Dobrovolskaia MA, Afonin KA.
ACS Biomaterials Science & Engineering. 2025. [PubMed Abstract]

Better the devil you know than the devil you don't - PEG challenges in nanomedicine.
Dobrovolskaia MA.
Nature Nanotechnology. 2025; 20(5): 580-583. [PubMed Abstract]

Nucleic acid nanobiosystems for cancer theranostics: an overview of emerging trends and challenges.
Rebolledo LP, Andrade LNS, Bajgelman MC, Banks L, Breakefield XO, Dobrovolskaia MA, Dokholyan NV, Kimura ET, Villa L, Zerbini LF, Zucolotto V, Afonin KA, Strauss BE, Chammas R, de Freitas Saito R.
Nanomedicine (Lond). 2025: 1-18. [PubMed Abstract]

IFN-gamma/IL-2 double-color fluoroSpot assay for monitoring human primary T cell activation: Validation, inter-laboratory comparison, and recommendations for clinical studies.
Mauthe A, Cedrone E, Villar-Hernandez R, Rusch E, Springer M, Schuster M, Preyer R, Dobrovolskaia MA, Gutekunst M.
AAPS Journal. 2025; 27(4): 81. [PubMed Abstract]

Preclinical SC and IV repeat-dose toxicology of a cowpea mosaic virus - A cancer immunotherapy candidate.
Stern ST, Affonso de Oliveira JF, Gatus J, Edmondson E, Neun BW, Dobrovolskaia MA, Steinmetz NF.
Toxicology Reports. 2025; 14: 102022. [PubMed Abstract]

Nanoparticles may influence mast cells gene expression profiles without affecting their degranulation function.
Newton HS, Cedrone E, Grunberger J, Xie S, Zhao Y, Tran B, Toms BS, Xu W, Plant-Hatley A, Liptrott NJ, Dobrovolskaia MA.
Nanomedicine. 2025; 66: 102818. [PubMed Abstract]

Target-specific locked nucleic acid gapmer decreases growth and metastases of pancreatic cancer.
Smith JP, Shivapurkar N, Chen W, Chekuri G, Dabney A, Holmes K, Cao, H, Kularatne R, Stern ST.
Mol Cancer Ther. 2025. [PubMed Abstract]

PLS-alpha-GalCer: a novel targeted glycolipid therapy for solid tumors.
Burks J, Tiwary S, Stevens DM, Skoczen SL, Kularatne RN, Stern ST, Berzofsky JA.
J. Immunother. Cancer. 2025; 13(3): e009539. [PubMed Abstract]

 

For a more comprehensive list of NCL publications, visit our MyNCBI bibliography page.

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Publications from the Nanotechnology Characterization Lab was originally published by the National Cancer Institute.”

Email